BioCentury
ARTICLE | Clinical News

Zafgen plans Phase II trial of next-generation MetAP2

May 4, 2017 11:10 PM UTC

Zafgen Inc. (NASDAQ:ZFGN) added $0.81 (17%) to $5.68 in early after-hours trading Thursday after reporting results of a Phase I trial of ZGN-1061, its next-generation second-generation methionine aminopeptidase 2 (MetAP2) inhibitor. Next half, the company intends to start a Phase II trial of the candidate in overweight or obese Type II diabetics.

The company said last year it would focus on ZGN-1061 after it discontinued development of another MetAP2 inhibitor, subcutaneous beloranib (ZGN-440). Two patients had died in a Phase III study of beloranib to treat Prader-Willi syndrome (see BioCentury Extra, July 19, 2016)...

BCIQ Company Profiles

Zafgen Inc.